3 Reasons the Bears Are Wrong About Valeant Pharmaceuticals

These respected contrarian investors may still have a few holes in their bearish arguments.

Mar 24, 2014 at 2:30PM

Contrarian investor Jim Grant recently wrote that he's "confidently bearish" on Valeant Pharmaceuticals (NYSE:VRX) in a Grant's Interest Rate Observer article, making his case against the skin- and eye-care drugmaker. The piece, which credits respected short-seller Jim Chanos for the initial idea, pushed the stock down 5% on publication. But does its bear case hold up to scrutiny? To find out, I examined a few of its major arguments, which are largely attributed to Evan Lorenz, an analyst at Grant's Interest Rate Observer.

1. Adjusted Numbers
Valeant provides auditor-approved GAAP financial statements, but also reports a number of non-GAAP measures, such as "Cash EPS." It also provides quite a few different ways to gauge organic growth. Lorenz concludes that Valeant's use of non-GAAP measures is an attempt to mask the company's true performance.

Certainly, there are examples of companies using non-GAAP numbers to mislead investors -- but I don't think that's the case here. Valeant is growing rapidly and via acquisitions, which has made the GAAP financials quite difficult to interpret. I've been through the company's GAAP financials and its reconciliation of "Cash EPS" to GAAP EPS. In my opinion, this additional measure helps investors understand the business' underlying economics. In short, what Lorenz interprets as obfuscation, I consider transparency.

2. Overvalued
Lorenz also implies that the company is overvalued based on free cash flow (defined as cash flow from operations minus capital expenditures). He says: "In 2013, free cash flow amounted to $927 million, or $2.89 per common share... The 2013 reading would give Valeant a less-than-lordly free-cash flow yield of 2 percent." Admittedly, the trailing free cash flow yield of 2% is quite meager, and I won't quibble with his calculation of free cash flow for 2013.

However, I find this claim highly flawed. Valuation is based on future profits, and historic numbers for Valeant don't necessarily indicate its future as well. The company is regularly acquiring companies that will increase future earnings power, and using backward-looking numbers doesn't account for this. For instance, the full effect of Valeant's $8.7 billion purchase of Bausch & Lomb, which closed in August of 2013, won't be seen in its 2013 numbers.

3. Declining organic revenue
It depends on which measure you use (same-store sales or pro forma), but Valeant reported 2013 organic growth of 0% to 2%. This has led Grant and Lorenz to conclude that the company's acquisition strategy isn't working. Grant says: "We don't see the data to support the contention [that acquisitions will bear fruit]." And Lorenz claims that "the longer a business is under a Valeant umbrella, the worse it performs." The implication is that Valeant is acquiring declining assets, which may temporary boost sales, but will eventually prove to be poor investments. Of all the bear arguments, serious investors should give this the most consideration.

Even so, I don't find it compelling. Although I'll keep continue to keep a close eye on organic growth, Valeant's results don't look bad enough for me to conclude that it's making poor acquisitions. More importantly, the track record and incentives of Valeant's management and board of directors give me confidence. CEO Mike Pearson has a great track record, and he owns more than $700 million worth of shares that he's committed to hold until at least 2017. ValueAct Capital, a savvy activist hedge fund with $2.9 billion invested in Valeant, has a board seat.

In conclusion...
As an investor, it's important to be humble. Bear arguments are always worth a look, especially when they come from respected people such as Jim Grant or Jim Chanos. But while the bears are often right, that doesn't seem to be the case here. Based on my examination of the arguments, the bears haven't found a smoking gun.

Right now, it seems like the market is reacting more to the notoriety and name-value of Grant and Chanos than to a compelling bear argument. Investors in Valeant shouldn't look to sell their shares based on this bear case. If anything, it could even represent an opportunity to buy shares at a better price.

6 stock picks poised for incredible growth
It's difficult to find growth stocks like Valeant at a great price -- in fact, many have said it can't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Brendan Mathews owns shares of Valeant Pharmaceuticals. The Motley Fool recommends Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information